HCM
Price
$16.45
Change
+$0.58 (+3.65%)
Updated
Aug 15 closing price
Capitalization
2.73B
89 days until earnings call
KNSA
Price
$33.38
Change
+$0.10 (+0.30%)
Updated
Aug 15 closing price
Capitalization
2.47B
79 days until earnings call
Interact to see
Advertisement

HCM vs KNSA

Header iconHCM vs KNSA Comparison
Open Charts HCM vs KNSABanner chart's image
HUTCHMED (China)
Price$16.45
Change+$0.58 (+3.65%)
Volume$34.06K
Capitalization2.73B
Kiniksa Pharmaceuticals International
Price$33.38
Change+$0.10 (+0.30%)
Volume$588.65K
Capitalization2.47B
HCM vs KNSA Comparison Chart in %
Loading...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. KNSA commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a Hold and KNSA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (HCM: $16.45 vs. KNSA: $33.38)
Brand notoriety: HCM and KNSA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 56% vs. KNSA: 69%
Market capitalization -- HCM: $2.73B vs. KNSA: $2.47B
HCM [@Pharmaceuticals: Generic] is valued at $2.73B. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $2.47B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 0 FA rating(s) are green whileKNSA’s FA Score has 0 green FA rating(s).

  • HCM’s FA Score: 0 green, 5 red.
  • KNSA’s FA Score: 0 green, 5 red.
According to our system of comparison, KNSA is a better buy in the long-term than HCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 5 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).

  • HCM’s TA Score: 5 bullish, 6 bearish.
  • KNSA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than HCM.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а +9.67% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +3.83% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

HCM is expected to report earnings on Nov 14, 2025.

KNSA is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HCM($2.73B) has a higher market cap than KNSA($2.47B). KNSA has higher P/E ratio than HCM: KNSA (667.60) vs HCM (6.21). KNSA YTD gains are higher at: 68.756 vs. HCM (14.157). HCM has higher annual earnings (EBITDA): 14.1M vs. KNSA (5.98M). HCM has more cash in the bank: 836M vs. KNSA (308M). KNSA has less debt than HCM: KNSA (9.77M) vs HCM (89.8M). HCM has higher revenues than KNSA: HCM (630M) vs KNSA (529M).
HCMKNSAHCM / KNSA
Capitalization2.73B2.47B110%
EBITDA14.1M5.98M236%
Gain YTD14.15768.75621%
P/E Ratio6.21667.601%
Revenue630M529M119%
Total Cash836M308M271%
Total Debt89.8M9.77M920%
FUNDAMENTALS RATINGS
HCM vs KNSA: Fundamental Ratings
HCM
KNSA
OUTLOOK RATING
1..100
6123
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
7391
PRICE GROWTH RATING
1..100
5339
P/E GROWTH RATING
1..100
10037
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HCM's Valuation (88) in the Pharmaceuticals Major industry is in the same range as KNSA (96). This means that HCM’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for HCM (100). This means that KNSA’s stock grew somewhat faster than HCM’s over the last 12 months.

HCM's SMR Rating (73) in the Pharmaceuticals Major industry is in the same range as KNSA (91). This means that HCM’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as HCM (53). This means that KNSA’s stock grew similarly to HCM’s over the last 12 months.

KNSA's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for HCM (100). This means that KNSA’s stock grew somewhat faster than HCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMKNSA
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 20 days ago
73%
Bullish Trend 5 days ago
74%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 24 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRREX18.330.10
+0.55%
Virtus Duff & Phelps Real Estate Secs R6
QUASX62.850.05
+0.08%
AB Small Cap Growth A
SZCAX50.57-0.08
-0.16%
DWS Small Cap Core A
JRAIX96.55-0.25
-0.26%
Janus Henderson Research I
BMPEX27.72-0.09
-0.32%
Beck Mack + Oliver Partners

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and CGC have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and CGC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
+3.65%
CGC - HCM
23%
Poorly correlated
-12.75%
OGI - HCM
22%
Poorly correlated
-8.33%
CRON - HCM
22%
Poorly correlated
-5.95%
AQST - HCM
22%
Poorly correlated
N/A
KNSA - HCM
22%
Poorly correlated
+0.30%
More

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+0.30%
COYA - KNSA
39%
Loosely correlated
+8.18%
JBIO - KNSA
37%
Loosely correlated
+8.71%
SNDX - KNSA
36%
Loosely correlated
+6.86%
CPRX - KNSA
35%
Loosely correlated
+0.80%
ATXS - KNSA
35%
Loosely correlated
+1.33%
More